Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 3/20 | 0.40 |
| ▸ | DKK1 | O94907 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16334101 | 0.84 | ALDH1A1 (0.46) | KDM4EPDE10ALMNAMAPTALDH1A1 | |
| SCHEMBL21832083 | 0.79 | KDM4E (0.47) | KDM4EPDE10ALMNAALDH1A1 | |
| SCHEMBL274998 | 0.77 | SLC6A2 (0.41) | KDM4ELMNAALDH1A1 | |
| SCHEMBL21713065 | 0.77 | SMO (0.40) | PDE10AMAPTALDH1A1 | |
| SCHEMBL275533 | 0.75 | PDE10A (0.54) | PDE10A | |
| SCHEMBL275522 | 0.74 | GLP1R (0.38) | PDE10AOGAMAPTALDH1A1 | |
| SCHEMBL276023 | 0.74 | PDE10A (0.37) | PDE10A | |
| SCHEMBL275614 | 0.73 | CNR2 (0.38) | PDE10A | |
| SCHEMBL276092 | 0.73 | GLP1R (0.38) | PDE10A | |
| SCHEMBL275589 | 0.73 | ALDH1A1 (0.42) | KDM4EPDE10ALMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237605-A1 | Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative | WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.) | 2011-09-29 | — | — | US | disclosed |
| US-20110237605-A1 | Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative | WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.) | 2011-09-29 | — | — | US | disclosed |
| WO-2011119282-A1 | MOLECULAR CRYSTAL OF (4 -(1,8-NAPHTHYRIDIN-2-YL) PIPERIDIN - 1 -YL ) PYRIMIDINE DERIVATIVE | BAUSCH & LOMB INCORPORATED (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119282-A1 | MOLECULAR CRYSTAL OF (4 -(1,8-NAPHTHYRIDIN-2-YL) PIPERIDIN - 1 -YL ) PYRIMIDINE DERIVATIVE | BAUSCH & LOMB INCORPORATED (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237605-A1 | Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative | PDGFRA, FLT1, PDGFRB | NPC1 3036/4885RAB9A 1343/4885KDM4E 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.